After 20 years of fighting a rare blood disease, Maureen joined an MSK trial, led by Dr. Heather Landau. Dr. Karlo Perica explains how #CART therapy re-engineered her immune cells to attack the disease. Just one week after her CAR T cell infusion, Maureen’s blood tests were normal.
The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system
www.nature.com/articles/s41...
📢 Today we celebrate International Day of LGBTQIA+ People In STEM!
📷 A drop of rainbow” (Lara Barrio): 🔴🟢🔵 With just three fluorescent markers it's possible to generate 7 colour combinations that allow researchers to track multiple cell populations in #Drosophila.
#LGBTQSTEMDay #PrideInSTEM
🧪
Thank you for the recognition! ☺️ @mskcancercenter.bsky.social @mskeducation.bsky.social
We're back with another exciting session — this time, spotlight on microglial cells!
And wait until you see our star-studded lineup of speakers!
Don't miss it — join us and stay at the forefront of the latest research!
@soyonhonglab.bsky.social
#WGC #GLIA
I'm excited to share that I've been selected to join the Life Sciences Technology Innovation Fellows Program at Cornell SC Johnson College of Business. The future is bright! @scjohnsoncollege.bsky.social #entrepreneurship #science
Single-cell RNA sequencing of immune cells for over 1,000 people age 18-97 years. A clock of our immune system aging. Tells us about an individual's response to infection, vaccination, Long Covid. Towards an immunome.
www.nature.com/articles/s43...
Going to the 2025 #MIT #European #Career #Fair this weekend, & wondering how to #fund your future #research?
Visit the 🇪🇺 European Union's stand to find out all about European Research Council's #grants!
Info 👉 europa.eu/!M4MWm8
#EURAXESS #Europe #Science #Grant #Funding @mitofficial.bsky.social
Functional differences between rodent and human PD-1 linked to evolutionary divergence | Science Immunology www.science.org/doi/10.1126/...
Carisma Therapeutics reports Phase 1 results of CT-0508, an anti-HER2 CAR #macrophage that has already been deprioritized, in advanced/metastatic #HER2 overexpressing solid tumors (14 pts). CAR-M therapy is feasible and well-tolerated.
@natmedicine.bsky.social
www.nature.com/articles/s41...
